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Abstract
The incidence of age-related macular degeneration (AMD), the main cause of blindness in older patients in the developed
countries, is increasing with the ageing population. At present there is no effective treatment for the prevailing geographic
atrophy, dry AMD, whereas antiangiogenic therapies successful used in managing the wet form of AMD. Recently we
showed that mitochondria-targeted antioxidant plastoquinonyl-decyl-triphenylphosphonium (SkQ1) is able to prevent the
development and moreover caused regression of pre-existing signs of the retinopathy in OXYS rats, an animal model of
AMD. Here we examine the effects of SkQ1 on expression of key regulators of angiogenesis vascular endothelial growth
factor A (VEGF) and its antagonist pigment epithelium-derived factor (PEDF) genes in the retina of OXYS rats as evidenced
by real-time PCR and an ELISA test for VEGF using Wistar rats as control. Ophthalmoscopic examinations confirmed that
SkQ1 supplementation (from 1.5 to 3 months of age, 250 nmol/kg) prevented development while eye drops SkQ1 (250 nM,
from 9 to 12 months) caused some reduction of retinopathy signs in OXYS rats and did not reveal any negative effects on
the control Wistar rat’s retina. Prevention of premature retinopathy by SkQ1 was connected with an increase of VEGF mRNA
and protein in OXYS rat’s retina up to the levels corresponding to the Wistar rats, and did not involve changes in PEDF
expression. In contrast the treatment with SkQ1 drops caused a decrease of VEGF mRNA and protein levels and an increase
in the PEDF mRNA level in the middle-aged OXYS rats, but in Wistar rats the changes of gene expression were the opposite.
Conclusions: The beneficial effects of SkQ1 on retinopathy connected with normalization of expression of VEGF and PEDF in
the retina of OXYS rats and depended on age of the animals and the stage of retinopathy.
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Introduction
Age-related macular degeneration is the most important cause
of impaired vision and blindness in the aging population. But its
pathogenesis remains poorly understood. The prevalence of age-
related diseases is increasing dramatically as the proportion of the
elderly in the population of developed countries continues to rise.
Therefore, the development of effective therapeutic and prophy-
lactic agents for AMD is urgently needed. Animal research as well
as observational studies suggests that antioxidant supplementation
can slow down aging of the eye and possibly provide some
protection against AMD [1,2]. Indeed, oxidative stress is
implicated in the aging process and pathogenesis of a wide range
of age-related disorders, including AMD. Nonetheless, random-
ized controlled trials show that antioxidant supplements do not
prevent early AMD [3]. There is no evidence that antioxidant
supplementation can reduce pre-existing signs of AMD. Moreover,
recent human studies reported an increased risk of adverse effects
associated with increased intakes of beta-carotene and vitamin E
[4]. At present there are tens of thousands of natural and synthetic
compounds that possess an antioxidant activity and the number is
growing. Correct assessment of antioxidant effects in humans is
difficult because of many factors, e.g., the long life span, high cost
of randomized controlled trials, ethical issues, and difficult-to-
control variables such as quality of life and individual differences in
nutrition and age-related health problems. Fortunately, animal
models can be used successfully to study biological effects of
antioxidants as well as molecular mechanisms and pathways
underlying those effects. We showed previously that the senes-
cence-accelerated OXYS rat strain is a suitable model for studying
the pathogenesis of AMD and for identifying the relevant
therapeutic targets [5–9].
The OXYS rat strain was developed at the Institute of Cytology
and Genetics, Siberian Branch of the Russian Academy of
Sciences, from Wistar stock by selection for susceptibility to
cataractogenic effects of galactose as described previously [10,11].
Progressive mitochondrial dysfunction is considered a possible
cause of accelerated senescence in OXYS rats [12,13] and a
possible source of enhanced reactive oxygen species (ROS)
production in the tissues of these animals [14]. And, indeed,
dietary supplementation with antioxidants can prevent the
premature deterioration of mitochondrial function typical for
OXYS rats. Recently, it was shown that the mitochondria-targeted
antioxidant SkQ1 (plastoquinonyl-decyl-triphenylphosphonium), a
conjugate of a lipophilic decyltriphenylphosphonium cation with
an antioxidant moiety of a plastoquinone [15], at nanomolar
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accelerated senescence in OXYS rats [7]. According to our data,
addition of the above-mentioned SkQ1 amounts to food or
treatment with SkQ1 eye drops not only completely prevents
development of retinopathy but also reduces the severity of pre-
existing pathological changes in the retina in OXYS rats [7]. This
implies improvement of the animals’ vision. It was reported that
the effects of SkQ1 include improvement of retinal pigment
epithelium functions and reduction of lipofuscin accumulation in
the OXYS rat retina [8].
The molecular mechanisms underlying the effects of SkQ1 have
yet to be investigated. It is known that in the course of aging, and
especially during the development of AMD, an impairment of
retinal angiogenesis occurs [16]. It is also known that the key
regulators of angiogenesis, vascular endothelial growth factor A
(VEGF-A, hereinafter referred to as VEGF) and pigment
epithelium-derived factor (PEDF), are involved in the pathogenesis
of AMD [17–20]. Recently, we reported accelerated reduction of
VEGF and PEDF gene expression in the retina of OXYS rats with
age in comparison with control (Wistar) rats [9], due to early
alterations in RPE cells and choroid vessels in OXYS rats. We
supposed that such changes are prerequisite for the development
of retinopathy.
The purpose of this study was to assess the effect of SkQ1 on
expression of VEGF and PEDF genes in the retina of OXYS rats
and to compare it with therapeutic effects of this antioxidant on
the signs of retinopathy in these animals. We investigated the
prophylactic effect of SkQ1 when added to food between the ages
of 1.5 to 3 months, which is the period of manifestation of early
signs of retinopathy [9]. In addition, we tested SkQ1 eye drops as a
possible therapeutic intervention from age 9 to 12 months, when
early alterations in the retina of OXYS rats actively progress to the
second stage of retinopathy [9].
Results
Ophthalmoscopic examination
Preliminary examination of rats at the age of 1.5 months
showed that the same percentage of eyes in experimental and
control groups of OXYS rats had signs of the 1st stage (1 a.u.) of
retinopathy (21 and 22%, respectively). SkQ1 supplementation of
food (from 1.5 to 3 months of age, 250 nmol/kg) prevented
development of retinopathy in OXYS rats (Fig. 1). Therefore at
the age of 3 months only 18% of OXYS rats’ eyes had signs of the
1st stage of retinopathy, whereas in 82% of eyes the signs of the
disease were not detected. In contrast, in untreated OXYS rats
retinopathy developed actively, and at the age of 3 months, 83%
and 17% of eyes had the signs of the 1st and 2nd stage of
retinopathy, respectively.
When assessing the therapeutic effect of SkQ1 eye drops during
the first examination of 9-month-old OXYS rats, all animals had
signs of retinopathy in at least one of the eyes. Sixty percent of eyes
in the control group (Fig. 2) presented with changes corresponding
to the AMD predisciform stage (1 a.u.), 5% corresponding to
disciform stage (2 a.u.), and 35% did not have the signs of
retinopathy. In the experimental group, 90% of eyes had changes
corresponding to the predisciform stage (1 a.u.), 7% corresponding
to the disciform stage (2 a.u.), and 3% of rats did not have the signs
of retinopathy.
Statistical analysis showed that SkQ1 reduced the severity of
pathological changes in the eye-ground of OXYS rats (p,0.000),
while in the control animals, retinopathy continued to progress
(p,0.0005) (Fig. 2). By the time of the second eye inspection at the
age of 12 months, in the control group, the percentage of eyes with
changes in the retina corresponding to the 2nd stage of
retinopathy (2 a.u.) had increased to 50%, and all eyes had signs
of retinopathy. At the time of re-examination of the SkQ1-treated
OXYS rats, we did not observe pathological changes in the eye-
ground of 17% of eyes, and the percentage of eyes with the 1st
stage retinopathy decreased to 77% (Fig. 2).
According to our recent research there is no any evidence of
retinopathy in the retina of Wistar rats up to 24 months [9]. The
results of this study are consistent with these data. We had not
detected any signs of retinopathy in the Wistar rat’s retina at the
first as well as the repeated inspection of eyes in both experiments
(SkQ1 supplementation and SkQ1 eye drops).
Expression of VEGF and PEDF genes
Effects of SkQ1 supplementation of food on gene
expression. Two-way ANOVA showed that VEGF mRNA
expression (Fig. 3a) was not affected by genotype (F1.23=0.27,
p=0.60) and by SkQ1 supplementation (F1.23=0.58, p=0.45),
but those factors were interacting (F1.23=5.35, p,0.029). One-
way ANOVA showed a decreased mRNA level of the VEGF gene
in the retina of control OXYS rats (F1.12=7.87, p,0.015)
Figure 1. Distribution of OXYS rat eyes by stage of retinopathy. Supplementation with 250 nmol SkQ1/kg per day starting at age 1.5 months
prevents the development of retinopathy in OXYS rats. ‘‘a.u.’’ are arbitrary units for estimation of degree of retinopathy (explained in Materials and
Methods).
doi:10.1371/journal.pone.0021682.g001
Therapeutic Action of SkQ1 on the Retinopathy
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e21682compared to the Wistar strain. SkQ1 supplementation did not
change VEGF mRNA expression in Wistar rats (p=0.29), but
increased it in OXYS rats (p,0.05) to the normal level of Wistar
rats (p=0.89).
VEGF protein level (Fig. 3b), according to two-way ANOVA,
was affected by genotype (F1.12=7.43, p,0.018) and was not
influenced by SkQ1 supplementation (F1.12=0.69, p=0.42),
although there was a significant interaction between the latter
two factors (F1.12=8.64, p=0.012). One-way ANOVA revealed a
difference between the level of VEGF protein in the retina of
untreated Wistar and OXYS rats (Fig. 3b). SkQ1 supplementation
increased VEGF protein expression in the retina of OXYS rats
(p,0.020) to the level of Wistar rats.
Expression of PEDF gene (Fig. 4a) was affected by genotype
(F1.27=16.35, p,0.0003) and was not influenced by SkQ1
(F1.27=0.0003, p=0.98). The latter two factors did not interact
with each other (F1.27=0.0001, p=0.99). One-way ANOVA
revealed a 47% lower level of PEDF mRNA in the retina of
untreated OXYS rats compared to untreated Wistar rats
(F1.13=10.18, p,0.007, Fig. 3a).
Figure 2. Distribution of OXYS rat eyes by stage of retinopathy. SkQ1 eye drops inhibit the development of retinopathy in OXYS rats,
averaged data. ‘‘a.u.’’ are arbitrary units for estimation of degree of retinopathy (explained in Materials and Methods).
doi:10.1371/journal.pone.0021682.g002
Figure 3. Effects of SkQ1 supplementation (250 nmol per kg of body weight per day) from age 1.5 to 3 months on (a) messenger
RNA (mRNA) expression (N=7) and (b) the protein level (N=4) of vascular endothelial growth factor (VEGF) in rat retina. Data are
presented as mean6SEM (standard error of the mean). * - in comparison with control; ‘ - in comparison with Wistar rats.
doi:10.1371/journal.pone.0021682.g003
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Expression of the VEGF gene (Fig. 5a) was affected by genotype
(F1.33=7.48, p,0.001) and was not influenced by SkQ1 (F1.33=
1.32, p=0.25). A significant interaction between these two factors
(F1.33=7.54, p=0.001) indicates that the SkQ1 eye drops affected
gene expression differently in the retinas of OXYS and Wistar rats.
One-way ANOVA analysis revealed no difference between the level
of VEGF mRNA in the retinas of untreated Wistar and OXYS rats
(Fig. 5a). SkQ1 significantly decreased VEGF mRNA expression in
the retina of OXYS rats (F1.18=5.21, p=0.034) and there was a
tendency for increased expression in the Wistar strain (F1.15=3.72,
p=0.072). As a result, the level of VEGF mRNA in SkQ1-drop-
treated OXYS rats matched the level of untreated Wistar rats
(F1.17=2.50, p=0.13) and became significantly lower than the
VEGF mRNA level of SkQ1-drop-treated Wistar rats (Fig. 5a;
F1.16=9.74, p=0.006).
A somewhat different situation was observed with the VEGF
protein level (Fig. 5b), which, according to two-way ANOVA,
depended only on the genotype and was lower in the OXYS retinas
(F1.12=35.16, p=0.000). One-way ANOVA showed a lower level
of VEGF protein in untreated OXYS rats than in untreated Wistar
rats. Interstrain comparison showed that SkQ1 eye drops had no
effect on the VEGF protein content in Wistar rats but significantly
reduced it in the retina of OXYS rats (p,0.017).
Expression of the PEDF gene (Fig. 4b) was affected by genotype
(F1.31=6.93, p,0.013) and was not influenced by SkQ1 eye drops
(F1.31=0.32, p=0.57). A significant interaction between the latter
two factors (F1.31=14.76, p=0.000) indicates that the SkQ1 eye
drops affected gene expression differently in the retinas of OXYS
and Wistar rats. One-way ANOVA revealed no difference
between the level of PEDF mRNA in the retinas of untreated
Wistar and OXYS rats (Fig. 4b). SkQ1 significantly increased
Figure 4. Effects of SkQ1 on retinal level of mRNA of pigment epithelium-derived factor (PEDF), N=8–10. Data are presented as
mean6SEM. (a) SkQ1 supplementation, 250 nmol per kg of body weight per day from 1.5 to 3 months of age; (b) SkQ1 eye drops (250 nM, one drop
per day) from age 9 to 12 months. * - in comparison with control, p,0.05; ‘ - in comparison with Wistar rats.
doi:10.1371/journal.pone.0021682.g004
Figure 5. Effects of SkQ1 eye drops (from 9 to 12 months of age) on (a) mRNA expression (N=8–10) and (b) protein level (N=4) of
vascular endothelial growth factor (VEGF) in rat retina. Data are presented as mean6SEM. * - in comparison with control; ‘ - in comparison
with Wistar rats.
doi:10.1371/journal.pone.0021682.g005
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p=0.033) and decreased it in Wistar rats (F1.13=11.55, p=0.004).
As a result, the level of PEDF mRNA in SkQ1-drop-treated
OXYS rats matched the level of untreated Wistar rats
(F1.16=1.94, p=0.18) and became significantly higher than the
PEDF mRNA level in SkQ1-drop-treated Wistar rats (Fig. 4b;
F1.15=18.42, p=0.0006).
Discussion
In our previous study [9] we identified two critical periods for
the development of clinical signs of retinopathy in OXYS rats.
The manifestation of early disease signs occurs between ages 1.5
and 3 months. Late stage retinopathy develops between 9 and 12
months of age [9]. Additionally, we showed that already at age 20
days the average area of open choroid vessels is decreased while
the area of thrombosed vessels is increased in OXYS rats
compared to (control) Wistar rats [9]. The developing atrophy of
blood vessels leads to hypoxic conditions in the outer retina.
Oxidative stress is the main mechanism of tissue damage under
hypoxia. In addition, oxidative stress may be both a cause and a
consequence of pathological changes in the retina. We found that
the mitochondria-targeted antioxidant SkQ1 [15,21] completely
prevents the development of early retinopathy signs in OXYS rats
when it is added to food starting from age 1.5 months.
Importantly, the antioxidant did not cause any changes in the
retina of Wistar rats. The fact that the eyes of the both control and
threaded with antioxidant groups of Wistar rats remained healthy
indicates that taking of SkQ1 does not have any negative effects.
As we showed recently doses of SkQ1 250 nmol/kg for
supplementation with food and 250 nM for eye drop are optimal
for retinopathy treatment, while 200-fold higher dose (drops
contain 25 mM SkQ1) can cause development of new vessels [7].
Same as previously [9], we now show that at age 3 months
expression of VEGF and PEDF genes in OXYS rats significantly
decreases in comparison with Wistar rats (controls) and it may
predispose retina to the development of early retinopathy. It
should be pointed out that the differences in mRNA expression of
both genes between OXYS and Wistar rats were much greater in
the previous [9] than in the present experiment. This difference
between the two experiments may be due to differences in the
severity of retinopathy. In the previous experiment [9] there were
25% of eyes with 2
nd stage and 75% with the 1
st stage disease in
OXYS rats, whereas now the figures are 17% and 83%
respectively. These data support the view that early retinopathy
(AMD) is associated with decreased expression of VEGF in the
retina. There are many reports in literature that support the
existence of a VEGF-mediated physiological mechanism that
ensures fine-tuning of choriocapillaris to the necessary nutrient
supply to the outer retina [15,22]. Thus, the premature decrease of
VEGF mRNA and protein levels in OXYS rats may cause a
disruption of this mechanism and thereby serve as both a cause
and a consequence of retinopathy.
We found that, at the molecular level, SkQ1 supplementation
prevents a decline of VEGF mRNA expression in OXYS rats and
increases protein expression to the normal level. This demon-
strates a link between VEGF expression and early retinopathy in
OXYS rats. Mitochondrial dysfunction of RPE cells is typical for
AMD and accompanies AMD pathogenesis in humans and, one
can assume, in rats as well as [23]. Mechanisms of therapeutic
action of SkQ1 on retinopathy involve renovation of mitochon-
drial structure and function in OXYS rats that lead to the reversal
of functional insufficiency of retinal pigment epithelium, which
produces VEGF and PEDF [7,21]. These therapeutic mechanisms
may also involve the ability of SkQ1 to act as a mitochondria-
targeted protonophore [24], which decreases reactive oxygen
species (ROS) generation and reduces oxidative damage in ocular
tissues. It is likely that SkQ1, acting on mitochondria, blocks
mitochondria-mediated apoptosis of RPE cells and photoreceptors
and thus prevents the atrophy of this tissue. Beneficial effects of
SkQ1 on the endothelium of choriocapillaris cannot be ruled out
either.
On the other hand, we did not observe any effects of SkQ1 on
PEDF expression at age 3 months—PEDF expression remains low
in SkQ1-treated and untreated OXYS rats compared to Wistar
rats. It is known that PEDF has anti-angiogenic properties, and
therefore we propose that SkQ1 either facilitates the creation of
blood vessels or somehow maintains the normal tissue metabolic
rate at age 3 months. It should be noted that this is the first study
to demonstrate a significant prophylactic effect of an antioxidant
compound on retinopathy. Our study also shows the influence of
an antioxidant on the expression of genes that are key for
retinopathy pathogenesis.
Additionally, we found that SkQ1 can work as a treatment for
pre-existing retinopathy in OXYS rats, when it is administered in
eye drops starting at age 9 months. In this case, the beneficial
effect of the antioxidant also affects the VEGF and PEDF gene
expression.
The development of late stage AMD is associated with increased
VEGF gene expression, especially in development of neovascu-
larization [25]. We did not observe an increased mRNA level of
either VEGF or PEDF at age 12 months—the age of onset of late
stage retinopathy—in OXYS rats compared to controls, just like in
our previous study [9]. Moreover, the protein level of VEGF is
decreased in OXYS rats compared to Wistar. In the present study,
we found almost no OXYS rats with detectable neovascularization
and this may be explained by the decreased level of VEGF. In
addition, we can hypothesize that the VEGF level is locally
increased because the amount of RPE cells, which produced
VEGF, is decreased according to morphologic analysis [9].
Immunohistochemical analysis would be needed to clarify this
question. Bhrutto and coworkers [20] have shown that the cause of
the increased VEGF level in late stage AMD is the immune cells
that migrate to the retina. It is possible that the development of
late stage retinopathy in OXYS rats occurs by the same scenario.
After treatment of OXYS rats with SkQ1 eye drops we also
observed changes in gene expression. In OXYS rats, the
antioxidant decreased VEGF mRNA and protein levels and
increased PEDF mRNA expression. At the same time, VEGF
expression (mRNA and protein) increased and PEDF mRNA
decreased in Wistar rats. We attribute the interstrain differences in
the response to SkQ1 eye drops to the different status of retina in
these rat strains. In OXYS rats the development of late stage
retinopathy is taking place, and therefore it is biologically
necessary to reduce VEGF activity in order to prevent edema
and neovascularization. In all experiments determination of
different splice isoforms of VEGF-A (for example VEGFXXXao r
VEGFA –XXXb) did not perform and is an aim of further
investigation of retinopathy in OXYS rats.
It is likely that SkQ1, which has anti-inflammatory properties
[21], suppresses the function of local immune cells (macrophages
and others), which are known to release VEGF [17]. In addition,
there are reports that SkQ1 prevents macrophage transformation
of RPE cells ex vivo [7]. Wistar rats do not exhibit clinical signs of
retinopathy, however conform to aging alterations of choroid
vessels and RPE occur in the retina of these rats. SkQ1, by
increasing VEGF level and decreasing PEDF expression, creates
the conditions for survival of choroid vessels in the retina of Wistar
Therapeutic Action of SkQ1 on the Retinopathy
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OXYS rats at age 3 months. This data allow us to suggest that
SkQ1 may inhibit development of the retinopathy as one of the
possible manifestations of the aging.
One more mechanism that mediates the effects of SkQ1 on
VEGF gene expression is the regulation of stability and
accumulation of the transcriptional factor hypoxia-inducible
factor-1 (HIF-1), which is the main regulator of VEGF expression
[17]. Recently, the crucial role of mitochondria-derived ROS for
activation HIF-1 was demonstrated and it was shown that the
suppression of mitochondrial generation of ROS by SkQ1
effectively blocked HIF-1 accumulation [26]. Additionally, we
would not rule out the anti-apoptopic action of this mitochondrial
antioxidant, which is mediated by its ability to block the opening of
non-specific pores in the mitochondrial membrane.
To date, there is no treatment for early AMD. Currently used
anti-VEGF agents typically stop the development of only the wet
form of AMD [27]. In the present study, we show that SkQ1 not
only prevents the development of early and late stage retinopathy
but also causes regression of pre-existing signs of the disease. At the
molecular level, we demonstrate normalization of VEGF mRNA
and protein levels by means of SkQ1 supplementation. It appears
that the effect of SkQ1 on gene expression depends on age of the
animals and the stage of retinopathy.
Methods
Ethics Statement
All animal procedures were in compliance with the Association
for Research in Vision and Ophthalmology statement for the Use
of Animals in Ophthalmic and Vision Research as well as the
European Communities Council Directive No. 86/609/EES. All
manipulations with animals were approved by Scientific Council
N 9 of the Institute of Cytology and Genetics Siberian Branch of
the Russian Academy of Sciences, according to ‘‘The Guidelines
for Manipulations with Experimental Animals’’ (the decree of the
Presidium of the Russian Academy of Sciences of April 02, 1980,
no. 12000-496).
Animals
Male senescence-accelerated OXYS and age-matched male
Wistar rats (as controls) were obtained from the Breeding
Experimental Animal Laboratory of the Institute of Cytology
and Genetics, Siberian Branch of the Russian Academy of
Sciences (Novosibirsk, Russia). At the age of 4 weeks, the pups
were weaned, housed in groups of five animals per cage
(57636620 cm), and kept under standard laboratory conditions
(2262uC, 60% relative humidity, and natural light), provided with
a standard rodent feed, PK-120-1, Ltd. (Laboratorsnab, Russia),
and given water ad libitum.
Studies of SkQ1 effects
SkQ1 was synthesized at the Institute of Mitoengineering of
Moscow State University (Moscow, Russia). Rats were distributed
among the control and experimental groups by simple random
sampling. To study the effects of SkQ1 on the development of
retinopathy in OXYS rats we conducted two experiments. In the
first experiment, 250 nmol SkQ1 per kg of body weight per day
were added to the feed of OXYS and Wistar rats between ages 1.5
and 3 months; the control groups of rats did not receive SkQ1. In
the second experiment, 0.9% NaCl solution (control group) or
250 nM SkQ1 in 0.9% NaCl (experimental group) was instilled to
the eyes of OXYS and Wistar rats in the amount of one drop day
in the form of eye drops from 9 to 12 months of age. In total, 60
animals were used in each experiment, 15 animals in each group
(OXYS control, OXYS experiment, Wistar control, and Wistar
experiment).
Ophthalmoscopic examination
All animals were examined by an ophthalmologist twice, before
and after SkQ1 supplementation or eye drop treatment, at the age
of 1.5 and 3 months or at the age of 9 and 12 months, respectively.
All rats underwent fundoscopy with a ‘‘Heine BETA 200 TL’’
Direct Ophthalmoscope (Heine, Germany) after dilatation with
1% tropicamide. Assessment of stages of retinopathy was carried
out according to the Age-Related Eye Disease Study (AREDS)
grade protocol (http://eyephoto.ophth.wisc.edu). The degree of
retinopathy was estimated as follows: 0 arbitrary unit (a.u.)
corresponds to health retina (Fig. 6a); 1 a.u. corresponds to
appearance of drusen and other pathological changes in the retinal
pigmented epithelium (RPE) and partial atrophy of the choroid
capillary layer (Fig. 6b); 2 a.u. means exudative detachment of
RPE and of retinal neuroepithelium, with further choroid capillary
layer atrophy (Fig. 6c. Five days after the last eye examination, the
rats were decapitated and the studies of the effects of the
mitochondria-targeted antioxidant SkQ1 on VEGF and PEDF
gene expression were performed. Kowa Genesis-D fundus camera
(Japan) was used as a hand-held digital fundus camera to take
digital fundus photographs of retina.
Studies of VEGF and PEDF gene expression
Steady-state mRNA expression of VEGF and PEDF was
studied in the retinas of the control and SkQ1-treated OXYS
and Wistar rats using real-time PCR. There were 7–10 animals in
each group. Rats were decapitated and eyes removed. The retina
for gene expression analysis was separated from the other tissues,
placed in microcentrifuge tubes for RNA isolation and frozen in
liquid nitrogen. All specimens were stored at –70uC prior to the
analysis.
Total cell RNA was isolated from rat retina using TRI-Reagent
(Ambion). The amount of isolated RNA was assessed by means of
electrophoresis of 1 ml of each RNA sample in 1.5% agarose gel
with ethidium bromide staining. RNA concentration in each
sample was determined using spectrophotometry at 260 nm and
also by absorbance ratios 260/280 nm and 260/320 nm. RNA
was stored at –70uC. Contaminating genomic DNA was removed
by treatment with DNase I (Promega, USA) according to the
vendor’s manual and then by repeated RNA extraction with the
phenol-chloroform mixture and pure chloroform, followed by
precipitation with propanol. Reverse transcription was performed
using M-MLV Reverse Transcriptase (Promega, USA). For
subsequent PCR, we used 0.25–1.0 ml of the resulting cDNA
solution.
Aliquots (4 ml) from all cDNA samples were mixed and the
‘‘average’’ solution was used for preparation of calibration curves,
which were used for determination of a relative cDNA level for
genes of interest and a reference gene in experimental samples.
Age-related changes of vegfa and pedf gene expression were
studied using iCycler iQ4 real-time PCR detection system (Bio-Rad
Laboratories, USA) and SYBR Green I dye (Molecular Probes,
USA). The housekeeping gene Rpl30 (encoding large ribosomal
subunit protein 30) was used as a reference gene. The following
primers were used: 59_ATGGTGGCTGCAAAGAAGAC_39 and
59_CAAAGCTGGACAGTTGTTGG_39 for Rpl30; 59_CTG-
GCTTTACTGCTGTACCTCCACC_39 and 59_GGCACACA-
GGACGGCTTGAA_39 for vegfa; and 59_GATTGCCCAG-
CTGCCTTTGACA_39 and 59_GGGACAGTCAGCACAGC-
TTGGATAG_39 for pedf.
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standard PCR buffer (67 mM Tris-HCl pH 8.9, 16 mM
(NH4)2SO4, 0.01% Tween 20, and 10 mM b-mercaptoethanol),
MgCl2 (3 mM for vegf, 1.5 mM for RPL30, and 3 mM for pedf),
0.2 mM dNTPs, SYBR Green I (1:20,000 dilution), 150 nM of
each primer, and 0.8 U of Taq polymerase (Institute of Cytology
and Genetics, Russia). Reaction was carried out under the
following conditions: heating at 95uC for 3 min (initial denatur-
ation), and then 40 cycles: denaturation at 95uC for 20 sec,
annealing at 60uC for 20sec, elongation at 72uC for 30 sec. Data
collection was based on fluorescence for Rpl30 at 84uC for 30 sec
and for the vegf and pedf genes at 87uC for 10 sec. After the
completion of PCR, the melting curves for specificity control were
recorded. In each experiment, samples of cDNA under study were
mixed with primers for a gene of interest (four repeats per cDNA
sample) in one microtube plate; similar samples were mixed with
primers for the reference gene (also four repeats). ‘‘Standard’’
cDNA was diluted from 1:2 to 1:64 with the same primers (2–3
repeats). For each cDNA sample, PCR was repeated at least twice.
To confirm amplicon size and reaction specificity, PAGE
electrophoresis was performed with DNA molecular weight
markers.
The initial quantitation of cDNA concentration in the samples
was carried out using standard calibration curves (versus
‘‘standard’’ cDNA) and the gene expression value was obtained
for each gene of interest; this value was then normalized according
to the amount of the reference gene cDNA [28].
Enzyme-Linked Immunosorbent Assay
Protein was isolated from rat retina using TRI-Reagent
(Ambion). Enzyme-linked immunosorbent assay (ELISA) for
VEGF (RayBiotech, USA) was performed according to the
manufacturer’s instructions, except that equal protein concentra-
tions were loaded into each well. Quantitation was carried out
according to the optical density measurement obtained using a
microtiter plate reader and recalculated as pg of VEGF protein
per mg of retinal tissue.
Statistical analysis
The data were analyzed using repeated measures ANOVA with
the statistical package Statistica 6.0. Two-way ANOVA was used
to evaluate effects of treatment. The independent variables were
genotype (Wistar, OXYS) and treatment (controls, SkQ1). A
Newman–Keuls post-hoc test was applied to significant main
effects and interactions in order to estimate the differences
between particular sets of means. One-way ANOVA was used
for individual group comparisons. To assess the therapeutic
effectiveness we performed dependent pairwise comparison of the
eye states before and after treatment (T-test for dependent
samples). Data are represented as mean 6 S.E.M. Results were
considered statistically significant if p value was less than 0.05.
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